Shaoyao Gancao Tang (SG-Tang), a formulated Chinese medicine, reduces aggregation and exerts neuroprotection in spinocerebellar ataxia type 17 (SCA17) cell and mouse models
- 13 February 2019
- journal article
- research article
- Published by Impact Journals, LLC in Aging
- Vol. 11 (3) , 986-1007
Abstract
Spinocerebellar ataxia (SCA) type 17 is an autosomal dominant ataxia caused by expanded polyglutamine (polyQ) tract in the TATA-box binding protein (TBP). Substantial studies have shown involvement of compromised mitochondria biogenesis regulator peroxisome proliferator-activated receptor gamma-coactivator 1 alpha (PGC-1α), nuclear factor erythroid 2-related factor 2 (NRF2), nuclear factor-Y subunit A (NFYA), and their downstream target genes in the pathogenesis of polyQ-expansion diseases. The extracts of Paeonia lactiflora (P. lactiflora) and Glycyrrhiza uralensis (G. uralensis) have long been used as a Chinese herbal medicine (CHM). Shaoyao Gancao Tang (SG-Tang) is a formulated CHM made of P. lactiflora and G. uralensis at a 1:1 ratio. In the present study, we demonstrated the aggregate-inhibitory and anti-oxidative effect of SG-Tang in 293 TBP/Q79 cells. We then showed that SG-Tang reduced the aggregates and ameliorated the neurite outgrowth deficits in TBP/Q79 SH-SY5Y cells. SG-Tang upregulated expression levels of NFYA, PGC-1α, NRF2, and their downstream target genes in TBP/Q79 SH-SY5Y cells. Knock down of NFYA, PGC-1α, and NRF2 attenuated the neurite outgrowth promoting effect of SG-Tang on TBP/Q79 SH-SY5Y cells. Furthermore, SG-Tang inhibited aggregation and rescued motor-deficits in SCA17 mouse model. The study results suggest the potential of SG-Tang in treating SCA17 and probable other polyQ diseases.Keywords
This publication has 72 references indexed in Scilit:
- A Review of Potential Harmful Interactions between Anticoagulant/Antiplatelet Agents and Chinese Herbal MedicinesPLOS ONE, 2013
- PGC-1α at the intersection of bioenergetics regulation and neuron function: From Huntington's disease to Parkinson's disease and beyondProgress in Neurobiology, 2012
- Antioxidants in Huntington's diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012
- Neuronal expression of TATA box-binding protein containing expanded polyglutamine in knock-in mice reduces chaperone protein response by impairing the function of nuclear factor-Y transcription factorBrain, 2011
- Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's diseaseNeurobiology of Disease, 2011
- Anti-inflammatory/Anti-oxidative Stress Activities and Differential Regulation of Nrf2-Mediated Genes by Non-Polar Fractions of Tea Chrysanthemum zawadskii and Licorice Glycyrrhiza uralensisThe AAPS Journal, 2010
- Nrf2 signaling and cell survivalToxicology and Applied Pharmacology, 2010
- Essential role of the unfolded protein response regulator GRP78/BiP in protection from neuronal apoptosisCell Death & Differentiation, 2009
- Mutant Huntingtin reduces HSP70 expression through the sequestration of NF‐Y transcription factorThe EMBO Journal, 2008
- The endoplasmic reticulum and the unfolded protein responseSeminars in Cell & Developmental Biology, 2007